The first batch of commercial products of the China-developed neutralizing antibody combination therapy against COVID-19 has been approved for the market in China on Thursday, the company said. Meanwhile the country has reported first cases caused by the fast transmitting BA.5.2 variant.

China’s domestic neutralizing antibody combination COVID-19 therapy products commercially enter market

The therapy, named BRII-196/BRII-198, jointly developed by Tsinghua University, the Third People’s Hospital of Shenzhen and Brii Biosciences, is the first novel coronavirus neutralizing antibody combination therapy drug with independent intellectual property rights approved in China. The product was approved for the market entry in December, 2021, for the treatment of adults and adolescents between 12 and 17 years old weighing over 40 kilograms, including individuals with mild and high risk factors for progression to severe conditions, including hospitalization or death. The therapy was then included in China’s 9th national combination COVID-19 therapy products diagnosis and treatment scheme in March 2022. Another treatment included in the scheme was imported Paxlovid developed by Pfizer.

The company said that in 2021, products providing the therapy were donated for 3,000 people to 22 hospitals in 21 cities across the country, while the Delta variant was striking China.Brii Biosciences had announced previously that its SARS-CoV-2 therapy BRII-196/BRII-198 demonstrated a statistically significant reduction of 78 percent in hospitalizations and deaths in phase III clinical trials conducted in the US, Brazil, South Africa, Mexico, Argentina and the Philippines. Studies in various independent labs over the world demonstrate that the combination COVID-19 therapy products remains efficacious against the BA.2 variant, the company said. Chinese researchfellows are rolling out a number of medications specific for COVID-19 treatment as the country is striving to fight against the rapidly mutating virus while upholding a dynamic zero-COVID strategy.

Source: This news is originally published by globaltimes

By Web Team

Technology Times Web team handles all matters relevant to website posting and management.